Strong Sephience Launch
Sephience generated $19.6 million in revenue within the quarter, with $14.4 million in the U.S. and $5.2 million ex-U.S. The company received 521 patient start forms from U.S. centers as of September 30.
Positive Financial Guidance
PTC Therapeutics narrowed its full-year revenue guidance to $750 million to $800 million, the upper end of the initial range.
Robust Phe Reduction Data
The AMPLIFY study demonstrated Sephience resulted in an average of 70% greater reduction in phenylalanine levels compared to BH4, highlighting its efficacy.
Strong Cash Position
PTC ended the third quarter with approximately $1.68 billion in cash, enabling strategic growth and R&D activities.